The interview underscores the persistently poor outcomes in pancreatic cancer and the continued reliance on chemotherapy, with fitness/tolerability driving the choice between FOLFIRINOX and gemcitabine-capecitabine. It highlights limited routine profiling beyond BRCA1/2, real-world reimbursement barriers to novel agents, and growing interest in strategies to “heat up” an immune-cold tumor microenvironment using CD73, TGF-β2 pathway strategies, alongside emerging modalities such as TTFields and CLDN18.2-directed ADCss.

This interview was conducted on 23 July 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.